EC Number |
Inhibitors |
Structure |
---|
3.4.24.B12 | more |
no inhibition by matrix metalloprotease inhibitor XS309 |
|
3.4.24.B12 | more |
[3S-[3R*,2-[2R*,2-(R*,S*)]-hexahydro-2-(2-[2-(hydroxyamino)-1-methyl-2-oxyethyl])-4-methyl-1-oxypentyl]-N-methyl]-3-pyridazinecarboxamide, i.e.XS309 is inactive at less than 0.01 mM in blocking ADAMTS-5 |
|
3.4.24.B12 | more |
TIMP-1, TIMP-2 and TIMP-4 do not inhibit ADAMTS-5 |
|
3.4.24.B12 | more |
not inhibited by N-TIMP-1 or TIMP-2; the general proteolytic activitiy of ADAMTS-5 as measured with carboxymethylated transferrin is unaffected by concentrations up to 1 M NaCl |
|
3.4.24.B12 | more |
substrate specificity of ADAMTS-5 against recombinant aggrecan, aggrecan mutants S377Q and S377T lead to aggrecan cleavage inhibition |
|
3.4.24.B12 | more |
lower expression level in majority of primary tumors |
|
3.4.24.B12 | more |
design of ADAMTS-5 inhibitors |
|
3.4.24.B12 | more |
design and development for potent and selective inhibitors of ADAMTS-4 and ADAMTS-5 |
|
3.4.24.B12 | NaCl |
the activity is very low at or below 50 mM NaCl or above 500 mM NaCl |
|
3.4.24.B12 | heparin |
- |
|